Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1963 1
1969 1
1975 1
1985 1
1986 1
1987 2
1988 1
1989 3
1990 4
1991 1
1992 2
1993 4
1994 5
1995 1
1996 3
1997 2
1998 3
1999 4
2000 6
2001 7
2002 5
2003 5
2004 7
2005 8
2006 7
2007 8
2008 4
2009 5
2010 3
2011 2
2012 7
2013 11
2014 10
2015 5
2016 11
2017 8
2018 19
2019 14
2020 19
2021 22
2022 26
2023 26
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Results by year

Filters applied: . Clear all
Page 1
Systemic treatment for metastatic colorectal cancer.
Leowattana W, Leowattana P, Leowattana T. Leowattana W, et al. World J Gastroenterol. 2023 Mar 14;29(10):1569-1588. doi: 10.3748/wjg.v29.i10.1569. World J Gastroenterol. 2023. PMID: 36970592 Free PMC article. Review.
The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders.
Losurdo G, Salvatore D'Abramo F, Indellicati G, Lillo C, Ierardi E, Di Leo A. Losurdo G, et al. Int J Mol Sci. 2020 May 16;21(10):3531. doi: 10.3390/ijms21103531. Int J Mol Sci. 2020. PMID: 32429454 Free PMC article. Review.
Small intestinal bacterial overgrowth (SIBO) is a condition hallmarked by an increase in the concentration of colonic-type bacteria in the small bowel. Watery diarrhea, bloating, abdominal pain and distension are the most common clinical manifestations. ...
Small intestinal bacterial overgrowth (SIBO) is a condition hallmarked by an increase in the concentration of colonic-type bacteria i …
Curcumin and Colorectal Cancer: From Basic to Clinical Evidences.
Pricci M, Girardi B, Giorgio F, Losurdo G, Ierardi E, Di Leo A. Pricci M, et al. Int J Mol Sci. 2020 Mar 29;21(7):2364. doi: 10.3390/ijms21072364. Int J Mol Sci. 2020. PMID: 32235371 Free PMC article. Review.
We conducted a literature review to summarize studies investigating the relationship between curcumin and colorectal cancer (CRC). In vitro studies, performed on human colon cancer cell lines, showed that curcumin inhibited cellular growth through cycle arrest at the G2/M …
We conducted a literature review to summarize studies investigating the relationship between curcumin and colorectal cancer (CRC). In vitro …
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquenz MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. van de Haar J, et al. Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2. Nat Med. 2023. PMID: 36864254 Free PMC article. Clinical Trial.
Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial.
Repici A, Badalamenti M, Maselli R, Correale L, Radaelli F, Rondonotti E, Ferrara E, Spadaccini M, Alkandari A, Fugazza A, Anderloni A, Galtieri PA, Pellegatta G, Carrara S, Di Leo M, Craviotto V, Lamonaca L, Lorenzetti R, Andrealli A, Antonelli G, Wallace M, Sharma P, Rosch T, Hassan C. Repici A, et al. Gastroenterology. 2020 Aug;159(2):512-520.e7. doi: 10.1053/j.gastro.2020.04.062. Epub 2020 May 1. Gastroenterology. 2020. PMID: 32371116 Clinical Trial.
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Davis LE, et al. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23. J Clin Oncol. 2019. PMID: 31013172 Free PMC article. Clinical Trial.
Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION: The study met its primary end point, demonstrating activity of regorafenib in patients w …
Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including …
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Lonardi S, et al. J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. J Clin Oncol. 2023. PMID: 37535876 Clinical Trial.
Epigenomic reprogramming of therapy-resistant circulating tumor cells in colon cancer.
Bao-Caamano A, Costa-Fraga N, Cayrefourcq L, Rodriguez-Casanova A, Muinelo-Romay L, López-López R, Alix-Panabières C, Díaz-Lagares A. Bao-Caamano A, et al. Front Cell Dev Biol. 2023 Dec 21;11:1291179. doi: 10.3389/fcell.2023.1291179. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38188020 Free PMC article.
Epigenetic changes, such as DNA methylation, in tumor cells are involved in the development of acquired resistance during treatment. Here, we characterized the DNA methylation landscape of colon circulating tumor cells (CTCs) during cancer progression and therapy resistanc …
Epigenetic changes, such as DNA methylation, in tumor cells are involved in the development of acquired resistance during treatment. Here, w …
267 results